To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated).
Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS).
A total of 164 medical institutions in 11 countries.
A total of 1,690… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.